Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05517473
Other study ID # S65841
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 5, 2022
Est. completion date August 16, 2022

Study information

Verified date August 2022
Source Universitaire Ziekenhuizen Leuven
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, the investigators aim to collect data regarding the efficiency and safety of two dyes used intraoperatively in vitrectomy to stain intraocular tissues. These products have the necessary approvals to use during such operation,These are NOT experimental products.


Description:

To determine efficacy and safety of MONOBLUE DUAL View and MONOBLUE ILM View (study products) vital stains during vitrectomy surgery. Both study products are CE-marked and legally marketed in Europe. The data collection will serve as Post-Marketing Clinical Follow-up according MDR provisions. Retrospective data will also be collected for the two reference products: ILM Blue® (DORC) and Membrane Blue Dual® (DORC) to serve as control. For this purpose, patient data will be used that were collected in studies S61408 (Comparative study 23G vs 27G vitrectomy), S63610 (Comparative study 27G vitrectomy vs larger gauge surgery) and S64913 (EVA Nexus Field Observation Study). The expected effect of the study products is to provide the retinal surgeon with adequate aid in visualizing the membranes involved in the retinal pathology to treat, thanks to their staining capabilities. The performance of the study products is related to the visualization of retinal tissues (ILM and/or ERM) during the vitrectomy procedure, when these tissues cannot be distinguished accurately enough without staining. Their use allows for better identification of these tissues and facilitates their removal by the surgeon. The clinical benefit of using ophthalmic dyes is to increase the patient's ability to recover anatomically and functionally by allowing more precise surgery with an effective visualization tool. Along with collecting post-marketing clinical follow-up data on the subject products, the outcomes of the present study results may be used at the UZLeuven Hospital to decide to use Monoblue ILM View and/or Monoblue Dual View as standard-of-care, replacing Membrane Blue Dual and ILM Blue.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date August 16, 2022
Est. primary completion date August 16, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Adult patients who underwent for vitrectomy surgery where ILM and/or ERM removal is required: - Macular holes (ILM staining) - Macular pucker (ILM and ERM staining) - Vitreomacular traction (ILM staining) Exclusion Criteria: - Children aged <18 years - Vitrectomy for other indication than mentioned in 3.1 - Patients that have concomitant eye disease that may influence the outcome of the surgery, e.g. terminal glaucoma - Patients that did to comply to the postoperative examination visit 6-10 weeks after the surgery

Study Design


Locations

Country Name City State
Belgium UZ Leuven Leuven Vlaams Brabant

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary visualization of membranes visualization of membranes stained based on binary subjective evaluation. intraoperative (surgery day)
Secondary surgical help subjective assessment of surgical help provided by the product intraoperative (surgery day)
Secondary adverse events Rate and severity of potential study-related products adverse events 1 day after surgery
Secondary visual acuity Visual outcome at the last postoperative visit 6 weeks after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT04535622 - Efficacy of Exercise Program for Facedown Posture-related Pain After Retinal Surgery N/A
Completed NCT03572725 - Air Tamponade and Non-supine Positioning in Macular Hole Surgery. N/A
Completed NCT01471912 - Elongation of Foveal Tissue After Macular Hole Surgery N/A
Completed NCT03646695 - ILM Flap Transposition Versus ILM Peeling for Macular Holes: a Pilot Study N/A
Completed NCT06323902 - Autologous Platelet-rich Plasma as a Treatment for Macular Holes
Completed NCT01974310 - Postoperative Positioning After Surgery for Macular Holes N/A
Completed NCT00537992 - Blue-Blocking IOLs in Combined Surgery N/A
Completed NCT05171621 - Measuring Subjective Quality of Vision and Metamorphopsia Before and After Epiretinal Membrane and Macular Hole Surgery
Recruiting NCT06000111 - Duration of Face Down Positioning for Full-Thickness Macular Hole Repair N/A
Recruiting NCT04135638 - Inverted ILM-flap Techniques Variants for Macular Hole Surgery: Outcomes Comparison N/A
Completed NCT03525899 - Macular Hole After Diabetic Vitrectomy
Completed NCT03917602 - Human Amniotic Membrane Plug for Large Macular Holes N/A
Completed NCT04527848 - Comparison of Two Intraocular Gas Injection Techniques in Macula Hole Surgery Phase 4
Recruiting NCT04116892 - Comparative Analysis of Large Macular Hole Surgeries N/A
Completed NCT01229657 - Evaluation of Anatomic and Visual Outcomes of Initially Closed Macular Holes N/A
Completed NCT01306487 - Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery N/A
Completed NCT01381965 - Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery N/A
Completed NCT03174639 - High Myopia Macular Hole and Retinal Detachment Treated With Double ILM Flaps N/A
Recruiting NCT05083650 - Large Macular Hole Closure Rate With Amniotic Membrane Graft With and Without Limitorrhexis N/A